Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | FGF1 | P05230 | 4/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | FGF2 | P09038 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 2/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17109659 | 1.00 | MMP13 (0.44) | MMP13MAOBFGF1SIRT2FGF2 | |
| SCHEMBL30891325 | 0.91 | HTT (0.46) | MMP13MAOBSIRT2HTTLGALS8 | |
| SCHEMBL30391620 | 0.91 | HTT (0.46) | MMP13MAOBSIRT2HTTLGALS8 | |
| SCHEMBL30391887 | 0.89 | MMP13 (0.45) | MMP13MAOBSIRT2HTTLGALS8 | |
| SCHEMBL29454879 | 0.89 | MMP13 (0.41) | MMP13MAOBFGF1FGF2HTT | |
| SCHEMBL30391867 | 0.88 | LMNA (0.43) | MMP13MAOBHTTLGALS8TGM2 | |
| SCHEMBL30661931 | 0.85 | MMP13 (0.40) | MMP13MAOBSIRT2HTTLGALS8 | |
| SCHEMBL30891318 | 0.85 | MMP13 (0.40) | MMP13MAOBSIRT2HTTLGALS8 | |
| SCHEMBL30391875 | 0.85 | MMP13 (0.43) | MMP13MAOBFGF1SIRT2FGF2 | |
| SCHEMBL25243911 | 0.85 | MMP13 (0.44) | MMP13MAOBLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9579391-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9265838-B2 | Conjugate based systems for controlled drug delivery | SMART CELLS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150265717-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9050370-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140274888-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | MMP13 707/4885MAOB 1722/4885FGF1 1398/4885 |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MMP13 707/4885MAOB 1722/4885FGF1 1398/4885 |
| US-20140274888-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MMP13 707/4885MAOB 1722/4885FGF1 1398/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MMP13 707/4885MAOB 1722/4885FGF1 1398/4885 |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MMP13 707/4885MAOB 1722/4885FGF1 1398/4885 |
| US-20150265717-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MMP13 707/4885MAOB 1722/4885FGF1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.